Safety and immunogenicity of Ad26.COV2.S in adolescents: phase 2 randomized clinical trial (2025)
Tica, Jelena; Rezelj, Veronica V.; Baron, Benoit; Zaidman, Javier; Fairlie, Lee; Scheper, Gert; Struyf, Frank; Douoguih, Macaya; Le Gars, Mathieu; Mussi, Marisa Márcia 
Source: Human Vaccines & Immunotherapeutics. Unidade: FMRP
Subjects: VACINAS, ADOLESCENTES, IMUNOGENICIDADE DA VACINA
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
TICA, Jelena et al. Safety and immunogenicity of Ad26.COV2.S in adolescents: phase 2 randomized clinical trial. Human Vaccines & Immunotherapeutics, v. 21, n. 1, p. 1-12, 2025Tradução . . Disponível em: https://doi.org/10.1080/21645515.2025.2450120. Acesso em: 19 jul. 2025.APA
Tica, J., Rezelj, V. V., Baron, B., Zaidman, J., Fairlie, L., Scheper, G., et al. (2025). Safety and immunogenicity of Ad26.COV2.S in adolescents: phase 2 randomized clinical trial. Human Vaccines & Immunotherapeutics, 21( 1), 1-12. doi:10.1080/21645515.2025.2450120NLM
Tica J, Rezelj VV, Baron B, Zaidman J, Fairlie L, Scheper G, Struyf F, Douoguih M, Le Gars M, Mussi MM. Safety and immunogenicity of Ad26.COV2.S in adolescents: phase 2 randomized clinical trial [Internet]. Human Vaccines & Immunotherapeutics. 2025 ; 21( 1): 1-12.[citado 2025 jul. 19 ] Available from: https://doi.org/10.1080/21645515.2025.2450120Vancouver
Tica J, Rezelj VV, Baron B, Zaidman J, Fairlie L, Scheper G, Struyf F, Douoguih M, Le Gars M, Mussi MM. Safety and immunogenicity of Ad26.COV2.S in adolescents: phase 2 randomized clinical trial [Internet]. Human Vaccines & Immunotherapeutics. 2025 ; 21( 1): 1-12.[citado 2025 jul. 19 ] Available from: https://doi.org/10.1080/21645515.2025.2450120
